Monoclonal antibodies against hepatitis B virus
US5204095A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jul 17, 1990 |
| Grant date | Apr 20, 1993 |
| Priority date | — |
| Expiry date | Jul 17, 2010 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/82
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The new hybridoma cell lines RF-HBs-1, RF-HBs-2 and RF-HBs-4 each secrete a nonoclonal antibody to hepatitis B surface antigen. The production of the antibodies may be carried out in vitro by culturing one of the cell lines or in vivo by establishing one of the cell lines as an ascites tumour in a mouse and isolating antibodies from the ascites fluid or from the serum. The antibodies have therapeutic, preventative and diagnostic uses in respect of hepatitis B virus infections and can be used to purify hepatitis B surface antigen. The relative specificities of the three monoclonal antibodies make them particularly useful in radiometric assay techniques employing specific combinations of the antibodies in solid phase.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.